Autor(es): Kieseier Bernd C.; Meyer Zu Hörste Gerd.; Lehmann Helmar C.; Gold Ralf; Hartung Hans-Peter

Resumo: The aim of this review is to describe the value of high-dose polyclonal intravenous immunoglobulins as a treatment option in autoimmune disorders affecting the peripheral nervous system. A randomized placebo-controlled trial in patients with chronic inflammatory demyelinating polyradiculoneuropathy revealed short-term and long-term efficacy and safety of intravenous immunoglobulins as a treatment option for the chronically inflamed peripheral nervous system. Case reports suggest that the subcutaneous administration of immunoglobulins may represent a convenient alternative. Intravenous immunoglobulin represents an effective and safe treatment option in patients with autoimmune-mediated diseases affecting the peripheral nerves.

Imprenta: Current Opinion in Neurology, v. 21, n. 5, p. 555-562, 2008

Identificador do objeto digital: 10.1097/WCO.0b013e32830efc03

Descritores: Guillain-Barre Syndrome - Cytopathology ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Inflammation ; Guillain-Barre Syndrome - Immunology ; Guillain-Barre Syndrome - Public health

Data de publicação: 2008

INDICADORES

ACESSO